52457-99-5

Basic information

• Product Name: N-(2-propanoylphenyl)acetamide
• Synonyms: N-(2-propanoylphenyl)acetamide;2'-PROPIONYLACETANILIDE
• CAS NO: 52457-99-5
• Molecular Formula: C₁₁H₁₃NO₂
• Molecular Weight: 191.23
• Mol File: 52457-99-5.mol

Chemical Properties

• Boiling Point: 376.5°Cat760mmHg
• Flash Point: 162.3°C
• Appearance: /
• Density: 1.121g/cm³
• Vapor Pressure: 7.2E-06mmHg at 25°C
• Refractive Index: 1.56
• CAS DataBase Reference: N-(2-propanoylphenyl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-propanoylphenyl)acetamide(52457-99-5)
• EPA Substance Registry System: N-(2-propanoylphenyl)acetamide(52457-99-5)

Safety Data

• Hazardous Substances Data: 52457-99-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-(2-propanoylphenyl)acetamide is used as an analgesic and antipyretic agent for its ability to relieve pain and reduce fever. It is effective in treating mild to moderate pain and fever by inhibiting the production of prostaglandins, which are responsible for these symptoms.
Used in Over-the-Counter Medications:
N-(2-propanoylphenyl)acetamide is used as an active ingredient in over-the-counter medications to provide relief from mild to moderate pain and fever. Its mild sedative effects also contribute to its popularity in these products.

InChI:InChI=1/C11H13NO2/c1-3-11(14)9-6-4-5-7-10(9)12-8(2)13/h4-7H,3H2,1-2H3,(H,12,13)

Upstream product

• 600-18-0 2-Oxobutyric acid 
• 103-84-4 Acetanilid 
• 123-38-6 propionaldehyde 
• 1885-29-6 anthranilic acid nitrile 
• 1196-28-7 2'-Aminopropiophenon 
• 75-36-5 acetyl chloride 
• 76466-74-5 3-[3-(O-acetamido)-phenyl]-propyl alcohol 
• 17408-15-0 1-(2-nitrophenyl)propanone 
• 108-24-7 acetic anhydride 

Downstream Products

• 10352-60-0 2,3-dimethylquinolin-4-ol 
• 1196-28-7 2'-Aminopropiophenon 
• 1642593-25-6 N-(2-(3-hydroxypent-1-yn-3-yl)phenyl)acetamide 
• 1642628-04-3 (E)-N-(4-ethylquinolin-2(1H)-ylidene)-4-methylbenzenesulfonamide 
• 124623-15-0 1-(2-amino-5-bromophenyl)propan-1-one 
• 63136-60-7 4-chloro-3-methylquinoline 
• 200617-77-2 acetic acid-(2-nitro-6-propionyl-anilide) 
• 188256-43-1 acetic acid-(4-nitro-2-propionyl-anilide) 
• 188256-42-0 N-(4-bromo-2-propanoylphenyl)acetamide 
• 857535-80-9 benzoic acid-(4-nitro-2-propionyl-anilide) 
• 857534-36-2 benzoic acid-(4-amino-2-propionyl-anilide) 
• 874488-29-6 1-(2-amino-3-nitro-phenyl)-propan-1-one 
• 124623-32-1 1-(2-amino-5-nitro-phenyl)-propan-1-one 

Relevant articles and documents

INHIBITORS OF ENL/AF9 YEATS

Methods and compositions for treating leukemia are disclosed. Acylated 6-aminoindoles, acylated 6-aminopyrrolopyridines and acylated 3-aminopyrrolo[3,2-c]pyridazines of the following formula inhibit ENL/AF9 YEATS and are therefore useful for treating leukemia.

Activation of C-H Activation: The Beneficial Effect of Catalytic Amount of Triaryl Boranes on Palladium-Catalyzed C-H Activation

Herein we report a novel approach to the acceleration of palladium-catalyzed C-H activation reactions. We demonstrated that the utilization of electron-deficient triaryl boranes as Lewis acidic cocatalysts of palladium enables the directed cross dehydrogenative coupling of aldehydes and anilides under mild reaction conditions. Study of the kinetic profile of the transformation reveals a unique, unexpectedly long induction period of the transformation.

FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS MODULATORS OF TNF ACTIVITY

A series of substituted heteroaromatic compounds containing two fused six- membered rings,tivity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and ne

Room temperature palladium-catalyzed decarboxylative ortho -acylation of acetanilides with α-oxocarboxylic acids

A novel Pd-catalyzed decarboxylative ortho-acylation of acetanilides with α-oxocarboxylic acids is realized at room temperature. This reaction provides efficient access to o-acyl acetanilides under mild conditions.

2-Arylaminopyrimidine derivatives as PLK inhibitors

Anilino-pyrimidine and 1,2,4-triazine compounds (1) are new. Anilino-pyrimidine and 1,2,4-triazine compounds of formula (1), their tautomers, racemates, enantiomers and/or diastereomers and acid-addition salts are new. X : NR 1a>, O or S; Y : CH or N; Z : hydrogen, halo, (halo)1-3C alkyl, 2-3C alkenyl, 2-3C alkynyl, formyl, 1-3C (halo)alkylcarbonyl, 2-3C alkenyl-, 2-3C alkynyl-carbonyl or pseudohalo; A : (hetero)aryl group (i) or (ii); R a> - R f>e.g. hydrogen, halo or nitro; R 1> and R 1a>hydrogen or methyl; R 2>e.g. Cl, Br, I, OR 6>; R 3>e.g. -CONR 1>-L-Q 3-Q 4-R 9>, -NR 1>-CO-L-Q 3-Q 4-R 9>; R 4>e.g. OR 6>, COR 6>, CONR 6>R 7>, NR 6>R 7>, NR 6>COR 7>, NR 6>SO 2R 7>, N=CR 6>R 7>, SR 6>, SOR 6>, SO 2R 6>, SO 2NR 6>R 7> or pseudohalogen, or any of 1-8C alkyl, 2-10C alkenyl or alkynyl, 3-8C cycloalkyl, (hetero)aryl or heterocyclyl; R 5>hydrogen, halo, trifluoromethyl, 1-3C alkyl or OR 6>; R 6>, R 7>e.g. hydrogen or any of 1-5C alkyl, 2-5C alkenyl or alkynyl, 3-10C cycloalkyl, (hetero)aryl or heterocyclyl; L : e.g. bond or residue of 1-16C alkyl, 2-16C alkenyl or alkynyl, 3-10C cycloalkyl, (hetero)aryl or heterocyclyl; Q 3 and Q 4bond or a mono- or bi-cyclic heterocyclyl, optionally substituted by one or more of Me, Et, halo, amino, hydroxy or pseudohalo; R 9>as L but not a bond; and T : N, O or S. Full definitions are given in the DEFINITIONS (Full Definitions) field. [Image] [Image] ACTIVITY : Cytostatic; Antiinflammatory; Immunosuppressive; Virucide; Anti-HIV; Dermatological; Nootropic; Neuroprotective; Nephrotropic; Vulnerary; Antibacterial; Fungicide; Antiparasitic; Antipsoriatic; Osteopathic; Cardiovascular-Gen; Vasotropic; Gastrointestinal-Gen. MECHANISM OF ACTION : Kinase inhibitor; Polo-like kinase (PLK) inhibitor. In a trial, (1) was found to have EC 50 against recombinant human PLK1 of below 5, generally 1 mu M. No results for specific compounds were given.

FIBROSIS INHIBITOR

Medicament being useful as a fibrosis inhibitor for organs or tissues, which comprises a compound of the formula (I): wherein Ring Z is optionally substituted pyrrole ring, etc.; W2 is -CO-, -SO2-, optionally substituted C1-C4 alkylene, etc.; Ar2 is optionally substituted aryl, etc.; W1 and Ar1 mean the following (1) and (2):(1) W1 is optionally substituted C1-C4 alkylene, etc.; Ar1 is optionally substituted bicyclic heteroaryl having 1 to 4 nitrogen atoms as ring-forming atoms:(2) W1 is optionally substituted C2-C5 alkylene, optionally substituted C2-C5 alkenylene, etc.; and Ar1 is aryl or monocyclic heteroaryl, which is substituted by carboxyl, alkoxycarbonyl, etc. at the ortho- or meta-position thereof with respect to the binding position of W1, or a pharmaceutically acceptable salt thereof.

Pyrrole derivatives

Pyrrole derivatives represented by the following formula: wherein Ring Z is an optionally substituted pyrrole ring, etc.; W2 is —CO—, —SO2—, an optionally substituted C1-C4 alkylene, etc.; Ar2 is an optionally substituted aryl, etc.; W2 and Ar1 mean the following (1) and (2): (1) W1 is an optionally substituted C1-C4 alkylene, etc.; Ar1 is an optionally substituted bicyclic heteroaryl having 1 to 4 nitrogen atoms as ring-forming atoms: (2) W1 is an optionally substituted C2-C5 alkylene, an optionally substituted C2-C5 alkenylene, etc.; and Ar1 is an aryl or monocyclic heteroaryl, which are substituted by carboxyl, an alkoxycarbonyl, etc. at the ortho- or meta-position thereof with respect to the binding position of W1, or a pharmaceutically acceptable salt thereof These compounds are useful as medicaments such as a fibrosis inhibitor for organs or tissues.